Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by da Rocha, A. B.
Right arrow Articles by Schwartsmann, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by da Rocha, A. B.
Right arrow Articles by Schwartsmann, G.
The Oncologist, Vol. 7, No. 1, 17-33, February 2002
© 2002 AlphaMed Press

Targeting Protein Kinase C: New Therapeutic Opportunities Against High-Grade Malignant Gliomas?

A. B. da Rocha, D.R.A. Mans, A. Regner, G. Schwartsmann

South-American Office for Anticancer Drug Development (SOAD), Comprehensive Cancer Center, Lutheran University of Brazil, Canoas, RS, Brazil

Correspondence: A. B. da Rocha, Ph.D., South-American Office for Anticancer Drug Development (SOAD), Comprehensive Cancer Center, Lutheran University of Brazil, Rua Miguel Tostes 101, predio 22,5o andar, 92420 -280 Canoas, RS, Brazil. Telephone:55-51-477-9219; Fax:55-51-478-1747; e-mail: brondani{at}terra.com.br

A large body of evidence suggests that the abnormal phenotype of neoplastic astrocytes, including their excessive proliferation rate and high propensity to invade surrounding tissues, results from mutations in critical genes involved in key cellular events. These genetic alterations can affect cell-surface-associated receptors, elements of signaling pathways, or components of the cell cycle clock, conferring a gain or a loss of relevant metabolic functions of the cells. The understanding of such phenomena may allow the development of more efficacious forms of cancer treatment. Examples are therapies specifically directed against overexpressed epidermal growth factor receptor, hyperactive Ras, excessively stimulated Raf-1, overproduced ornithine decarboxylase, or aberrantly activated cyclin-dependent kinases. The applicability of some of these approaches is now being assessed in patients suffering from primary malignant central nervous system tumors that are not amenable to current therapeutic modalities. Another potentially useful therapeutic strategy against such tumors involves the inhibition of hyperactive or overexpressed protein kinase C (PKC). This strategy is justified by the decrease in cell proliferation and invasion following inhibition of the activity of this enzyme observed in preclinical glioma models. Thus, interference with PKC activity may represent a novel form of experimental cancer treatment that may simultaneously restrain the hyperproliferative state and the invasive capacity of high-grade malignant gliomas without inducing the expected toxicity of classical cytotoxic agents. Of note, the experimental use of PKC-inhibiting agents in patients with refractory high-grade malignant gliomas has indeed led to some clinical responses. The present paper reviews the current status of the biochemistry and molecular biology of PKC, as well as the possibilities for developing novel anti-PKC-based therapies for central nervous system malignancies.

Key Words. Protein kinase C • High-grade malignant gliomas • Intracellular signaling • Mitogen-activated protein kinase/extracellular-signal-regulated kinase • Extracellular-signal-regulated kinases • Ornithine decarboxylase • Cell proliferation • Cell invasion




This article has been cited by other articles:


Home page
 CarcinogenesisHome page
S. Sarkar and V. W. Yong
Reduction of protein kinase C delta attenuates tenascin-C stimulated glioma invasion in three-dimensional matrix
Carcinogenesis, February 1, 2010; 31(2): 311 - 317.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. N. Kreisl, L. Kim, K. Moore, P. Duic, S. Kotliarova, J. Walling, L. Musib, D. Thornton, P. S. Albert, and H. A. Fine
A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas
Clin. Cancer Res., May 15, 2009; 15(10): 3617 - 3623.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K.-W. Lee, S. G. Kim, H.-P. Kim, E. Kwon, J. You, H.-J. Choi, J.-H. Park, B.-C. Kang, S.-A. Im, T.-Y. Kim, et al.
Enzastaurin, a Protein Kinase C{beta} Inhibitor, Suppresses Signaling through the Ribosomal S6 Kinase and Bad Pathways and Induces Apoptosis in Human Gastric Cancer Cells
Cancer Res., March 15, 2008; 68(6): 1916 - 1926.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J.-A. Park, A. L. Crews, W. R. Lampe, S. Fang, J. Park, and K. B. Adler
Protein Kinase C{delta} Regulates Airway Mucin Secretion via Phosphorylation of MARCKS Protein
Am. J. Pathol., December 1, 2007; 171(6): 1822 - 1830.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Amos, M. Mut, C. G. diPierro, J. E. Carpenter, A. Xiao, Z. A. Kohutek, G. T. Redpath, Y. Zhao, J. Wang, M. E. Shaffrey, et al.
Protein Kinase C-{alpha} Mediated Regulation of Low-Density Lipoprotein Receptor Related Protein and Urokinase Increases Astrocytoma Invasion
Cancer Res., November 1, 2007; 67(21): 10241 - 10251.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. A. DeVries-Seimon, A. M. Ohm, M. J. Humphries, and M. E. Reyland
Induction of Apoptosis Is Driven by Nuclear Retention of Protein Kinase C{delta}
J. Biol. Chem., August 3, 2007; 282(31): 22307 - 22314.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Podar, M. S. Raab, J. Zhang, D. McMillin, I. Breitkreutz, Y.-T. Tai, B. K. Lin, N. Munshi, T. Hideshima, D. Chauhan, et al.
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)
Blood, February 15, 2007; 109(4): 1669 - 1677.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. R. Slupsky, A. S. Kamiguti, R. J. Harris, J. C. Cawley, and M. Zuzel
Central Role of Protein Kinase C{epsilon} in Constitutive Activation of ERK1/2 and Rac1 in the Malignant Cells of Hairy Cell Leukemia
Am. J. Pathol., February 1, 2007; 170(2): 745 - 754.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. P. Jane, D. R. Premkumar, and I. F. Pollack
Coadministration of Sorafenib with Rottlerin Potently Inhibits Cell Proliferation and Migration in Human Malignant Glioma Cells
J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1070 - 1080.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Carducci, L. Musib, M. S. Kies, R. Pili, M. Truong, J. R. Brahmer, P. Cole, R. Sullivan, J. Riddle, J. Schmidt, et al.
Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer
J. Clin. Oncol., September 1, 2006; 24(25): 4092 - 4099.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. D. Dixit, A. T. Weeraratna, H. Yang, D. Bertak, A. Cooper-Jenkins, G. J. Riggins, C. G. Eberhart, and D. D. Taub
Ghrelin and the Growth Hormone Secretagogue Receptor Constitute a Novel Autocrine Pathway in Astrocytoma Motility
J. Biol. Chem., June 16, 2006; 281(24): 16681 - 16690.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. Saleem, S. Kaur, M.-H. Kweon, V. M. Adhami, F. Afaq, and H. Mukhtar
Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway
Carcinogenesis, November 1, 2005; 26(11): 1956 - 1964.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. R. Graff, A. M. McNulty, K. R. Hanna, B. W. Konicek, R. L. Lynch, S. N. Bailey, C. Banks, A. Capen, R. Goode, J. E. Lewis, et al.
The Protein Kinase C{beta}-Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts
Cancer Res., August 15, 2005; 65(16): 7462 - 7469.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Koivunen, V. Aaltonen, S. Koskela, P. Lehenkari, M. Laato, and J. Peltonen
Protein Kinase C {alpha}/{beta} Inhibitor Go6976 Promotes Formation of Cell Junctions and Inhibits Invasion of Urinary Bladder Carcinoma Cells
Cancer Res., August 15, 2004; 64(16): 5693 - 5701.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. D. Rochdi and J.-L. Parent
Galpha q-coupled Receptor Internalization Specifically Induced by Galpha q Signaling. REGULATION BY EBP50
J. Biol. Chem., May 9, 2003; 278(20): 17827 - 17837.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
T. T. Su, B. Guo, and D. J. Rawlings
Emerging Roles for PKC Isoforms in Immune Cell Function
Mol. Interv., June 1, 2002; 2(3): 141 - 144.
[Abstract] [Full Text]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2002 by AlphaMed Press.
Advertisement